Hospital Clínico Universitario de Santiago
Santiago de Compostela, A Coruña, 15706, Spain
Location status: Recruiting
Location contact
Carlos Peña-Gil, MD, PhD
CONTACT
Estíbaliz Díaz-Balboa
CONTACT
NCT Number: NCT06302634
The objective of this observational study is to assess the outcomes of a hospital-based Cardio-Oncology Rehabilitation (CORe) program focused on exercise in cancer patients undergoing cardiotoxic treatment. This evaluation will be conducted by analyzing disease-related health indicators, functional capacity, and quality of life. Patients at risk of cardiotoxicity attending the Cardio-Onco-Hematology Unit will be offered the exercise program, which includes two modalities: in-person (center-based) and remote (home-based) options. The assignment to either modality is non randomized, based on the functional assessment conducted in the Rehabilitation Unit and the agreement between healthcare professional and patient. All participants will perform a 3-month supervised exercise intervention. There are 3 time points for assessment: at baseline (T0), 3-month after the exercise program (T1) and follow-up at 9 months from baseline (T2).
Interested in participating?
Request Info18 year–70 year
All sexes
Observational
Santiago de Compostela, A Coruña, 15706, Spain
Location status: Recruiting
Carlos Peña-Gil, MD, PhD
CONTACT
Estíbaliz Díaz-Balboa
CONTACT
Advancements in pharmacological cancer treatment have significantly improved prognosis and increased survival rates. However, the chronicity of treatment-related side effects or associated comorbidities may be exacerbated. Various chemotherapy treatments are associated with the potential development of cardiovascular diseases, such as cardiotoxicity, which stands as a main cause of death among women with early-stage breast cancer. Additionally, other side effects, such as fatigue, loss of muscle mass, insomnia, lymphedema, and cognitive impairments, can markedly decline the quality of life of these patients.
The comprehensive care of oncology patients should extend beyond curative interventions like surgery, radiotherapy, or chemotherapy. It must encompass other aspects, such as psychological support, social support and therapeutic exercise programs to enhance the overall treatment experience and improve the quality of life. Exercise has proven to reduce mortality, morbidity, and the risk of recurrence, improving treatment tolerance and reducing interruptions, thereby promoting adherence. Supervised exercise programs are increasingly recognized as a low-cost and a side-effect-free "polypill". However, they have not yet been integrated into the standard care of patients with cancer.
The inherited experience from multimodal Cardiac Rehabilitation (CR) programs with a comprehensive assessment and a multifaceted intervention with exercise programs as a central component; could be extended to cancer patients, resulting in a CORe program (ReCO in Spanish) by utilizing available CR programs in all healthcare areas.
The proposed CORe care process is grounded in the prior experience with the ONCORE trial (Clinicaltrials.gov: NCT03964142), which has helped in the implementation of new, structured, and controlled healthcare service, ensuring higher quality, safety, and efficiency in healthcare.
The implementation of the CORe program will take place at the University Hospital Complex of Santiago de Compostela (CHUS), under the coordination of the Cardiology, Oncology, and Rehabilitation services. The management of participants data and the establishment of indicators should facilitate the monitoring of the process and the evaluation of the results of clinical interventions.
The goal of this project is to assess the outcomes of a CORe care process through the analysis of health-related indicators, functional capacity, and the quality of life of breast cancer participants attending the Cardio-Oncology Unit.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2); every year after study completion up to a maximum of 5 years
Fall of 10 absolute percentage points of left ventricular ejection fraction from baseline or with final value below 53% or global longitudinal strain fall >15% with respect to baseline
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2); every year after study completion up to a maximum of 5 years
cTnI/T>percentil 99, BNP≥35 pg/mL, NT-proBNP≥125 pg/mL
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
To estimate VO2peak, the ONCORE equation developed in the following article is used: Díaz-Balboa, E., González-Salvado, V., Rodríguez-Romero, B. et al. Thirty-second sit-to-stand test as an alternative for estimating peak oxygen uptake and 6-min walking distance in women with breast cancer: a cross-sectional study. Support Care Cancer 30, 8251-8260 (2022). https://doi.org/10.1007/s00520-022-07268-z
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2); every year after study completion up to a maximum of 5 years
Dyslipidemia, Diabetes mellitus, Arterial Hypertension, Smoking status
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2); every year after study completion up to a maximum of 5 years
Value of fasting blood glucose (mg/dL) in blood tests
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2); every year after study completion up to a maximum of 5 years
Value of LDL >160 mg/dL or CT> 200 mg/dL in blood tests
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2); every year after study completion up to a maximum of 5 years
Value of haemoglobin (g/dL) in blood tests
Time frame: Date of the event throughout the study.
number of participants with significant cardiovascular and non-cardiovascular adverse effects throughout the study, threatening life, requiring admission, prolonging hospitalization, being clinically relevant or causing chemotherapy interruptions.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Score achieved in the Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4) questionnaire, a specific validated scale to assess quality of life of women with breast cancer. It comprises 27 items within 5 areas of assessment: physical well-being (7 items), social and family environment (7 items), emotional well-being (7 items), functional well-being (6 items) and worries related to the diagnosis and treatment of the disease (9 items). Each item is scored by means of a Likert scale from 0 to 5, with higher scores representing better results. The total score is obtained by adding the scores for each item, and ranges from a minimum of 0 (worst possible result) to a maximum of 146 (best possible result).
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Number of repetitions in the sit-to-stand test within 30 seconds.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Kilograms by dynamometry.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Kilograms by dynamometry.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Thigh perimeter measured with a tape measure in cm.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
The peak expiratory flow in units of liters per minute (L/min), measured with a peak flow meter.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Grip strength (both right and left side) and bilateral biceps strength in kilograms by dynamometry.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Weight measured in kg.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Weight and height will be combined to report BMI in kg/m^2
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Abdominal perimeter measured with a tape measure in cm.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Resting heart rate by pulse oximetry (beats per min).
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2)
Resting blood pressure by a blood pressure monitor in mmHg.
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2).
Score achieved in the Godin Leisure Test Exercise Questionnaire (GLTEQ) for quantification of physical activity. Activities are classified into three subgroups: "strenuous," "moderate," and "light." The scores corresponding to the energy expenditure (metabolic equivalent (MET)) are obtained by multiplying activities performed for more than 15 min in a week with their coefficients. The numbers represent the MET intensity values (strenuous/ exhausting exercises: 9 METs, moderate exercises: 5 METs, and light exercises: 3 METs).The increasing scores are associated with the increasing number of exercise behaviors, providing references about the contribution of physical activity to health: the activity score of 24 units and more as active (substantial benefits); the activity score of 14-23 units as moderately active (some benefits); and the activity score of 13 units and less as inactive (less substantial or low benefits).
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2).
ACE Inhibitor/ARB II; Beta-blocker; Statins; Ezetimibe
Time frame: At the end of the cardiac rehabilitation program (3 months duration).
Number of training sessions attended / number of sessions planned.
Time frame: At the end of the cardiac rehabilitation program (3 months duration).
Number of telephone calls attended / number of telephone calls planned.
Time frame: At the end of the cardiac rehabilitation program (3 months duration).
Adverse events during training.
Time frame: At the end of the cardiac rehabilitation program (3 months duration).
Global satisfaction is scored from 0 (no benefit) to 10 (highest benefit); and evaluated with an open-ended question, how do you expect to benefit from participating in the program?
Time frame: At follow-up at 9 months from baseline (T2).
Question (yes/no): do you continue exercising? supervized? if supervized, is it individualized by a physiotherapist? individualized by a personal trainer? recommendations from a technician in a gym? or city council group activities?
Time frame: Baseline (T0); 3 months after completing the exercise program (T1); follow-up at 9 months from baseline (T2).
It is considered 2 cm difference between upper limbs. Measurement is performed at the base of the 3rd finger, hand, wrist, 10 cm above the wrist, elbow, 10 cm above the elbow and axilla.
Contact information is provided by the study sponsor or research team.
Bibiana Villamayor-Blanco, MD, PhD
CONTACT
Estíbaliz Díaz-Balboa, PT
CONTACT
Hospital Clinico Universitario de Santiago
Other
Hospital-based Cardio-Oncology Rehabilitation Care Process for Cardiovascular Health in Cancer Patients
Acronym: ReCO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06930521
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Toronto, Ontario, Canada
View Trial DetailsNCT07622394
Cancer Survivorship, Cancer Therapy-related Cardiac Dysfunction
Ürümqi, Xinjiang, China
View Trial DetailsNCT05216042
Behavior, Body Weight
Birmingham, Alabama, United States
View Trial DetailsNCT07019506
Aerobic Capacity, Behavior
Medellín, Colombia
View Trial Details